CNTO 530

Drug Profile

CNTO 530

Alternative Names: CNTO-530

Latest Information Update: 19 Nov 2010

Price : $50

At a glance

  • Originator Centocor
  • Developer Centocor Ortho Biotech; Edison Pharmaceuticals
  • Class Antianaemics; Antibodies; Recombinant fusion proteins
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Clinical Phase Unknown Haemoglobinopathies; Mitochondrial disorders
  • No development reported Thalassaemia

Most Recent Events

  • 19 Nov 2010 Clinical trials in Haemoglobinopathies in USA (Parenteral)
  • 19 Nov 2010 Clinical trials in Mitochondrial disorders in USA (Parenteral)
  • 05 Jan 2010 No development reported - Preclinical for Thalassaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top